Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

KAKEN PHARMACEUTICAL

Home Clinical Trial Sponsors and OrganizationsKAKEN PHARMACEUTICAL

KAKEN PHARMACEUTICAL

Japanwww.kaken.co.jpEstablished: 1948-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

10

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1948

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

5

50.0%

Phase 3

3

30.0%

Phase 2

2

20.0%

Trial Status Distribution

Completed

9

90.0%

Recruiting

1

10.0%

Clinical Trials

Trials sponsored by this organization (10)

A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

May 2026150 participants

To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

Feb 202538 participants

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

Oct 202424 participants

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

Oct 202440 participants

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

Dec 202338 participants

A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)

Nov 200925 participants

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

Jul 200958 participants

Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)

Aug 2008328 participants

Page 1 of 2

Approvals

No approval data available

News

Astria Therapeutics Secures $16 Million Japan Partnership for Hereditary Angioedema Treatment Navenibart

- Astria Therapeutics has granted exclusive development and commercialization rights for navenibart in Japan to Kaken Pharmaceutical in a deal worth up to $32 million. - Navenibart is a long-acting monoclonal antibody currently in Phase 3 trials designed for the preventative treatment of hereditary angioedema. - The partnership includes an upfront payment of $16 million, potential milestone payments of another $16 million, and tiered royalties up to 30 percent. - Kaken will support the ongoing ALPHA-ORBIT Phase 3 trial in Japan and manage regulatory submissions for commercialization.

On this page

Overview
Clinical Trials10
Approvals
News1

Back to Organizations